INTERVIEWS

Surgery is often a gateway to persistent opioid use. In this episode, Dr. Paul Sethi and Dr. Fred Muench share findings from the new Choices Matter Status Report, which examines opioid prescribing trends in the nation with a focus on the surgical setting.

Dr. Sean Ianchulev and Dr. Pamela Gallin discuss myopia and the positive results from its EYN PG21 proof-of-concept study demonstrating that its micro-dose of latanoprost successfully lowered intraocular pressure (IOP) and achieved patient usability.  

David Frazer, CEO of the National Pediatric Cancer Foundation (NPCF), discusses pediatric cancer and the fight to find less toxic, more targeted treatments. Ten drugs have been developed for use in children with cancer since 1980 as compared to hundreds created for adults. He talks about the progress and goal of the company.  

Gordon Naylor, President of Seqirus, an influenza vaccine company, joins us from ID Week 2018 in San Francisco to talk about Seqirus’ Pandemic Response Solutions team learning lounge presentation highlighting the constant threat of influenza pandemic, the importance of pandemic planning, and the advancements in flu prevention since the historical 1918 Flu Pandemic.

Brittany, a six-year-old who was diagnosed with Hepatoblastoma at 15 months old, and her mom, Vanessa, talk about the diagnosis and how the National Pediatric Cancer Foundation gave them hope. Hepatoblastoma is a rare form of liver cancer and it usually affects boys. About 1 in 1.5 million gets this disease.  

Sateria Venable, a fibroid sufferer who has endured four surgeries, launched the Fibroid Foundation to educate women and support initiatives to find reasonable medical solutions for fibroids. Although she does not have a medical background, Sateria has a deep knowledge of this health problem and recently co-authored a scientific paper that appeared in the “American Journal for Obstetrics and Gynecology“. She discusses her insight on the need for new treatments, including alternative therapies and treatments on the horizon for fibroid sufferers.

Ashleigh Palmer, CEO and co-founder of Provention Bio, Inc, discusses what the company is doing in developing novel therapeutics aimed at intercepting and preventing immune-mediated disease. For example, they are starting a Phase 3 trial for prevention of Type 1 Diabetes. They also have late-stage studies to intercept Crohn’s disease, ulcerative colitis, and lupus.

Rupen Patel, CEO of Influence Health, talks about a number of ways in which hospitals, health systems, and providers can both attract and retain patients by creating an Amazon-like personal and on-demand experience healthcare consumers have come to expect. He shares case examples of how traditional marketing practices are now being used at the clinical level as providers are seeking ways in which to adapt their customer relationship management (CRM) solution into a clinical tool that enables continuity of care, improves satisfaction scores and reduces readmissions.

Company President and CEO of OncoSec Immunotherapies, Dan O’Connor, discusses the company’s late-stage studies to treat and potentially cure advanced melanoma and triple negative breast cancers. Their technology turns cold tumors hot which then allows combo therapy to attack and destroy cancer cells from inside the body. Early bench studies show very positive results.